On May 5, 2025, Health Canada approved Teplizumab (brand name Tzield), the first-ever treatment that can delay the onset of type 1 diabetes (T1D) in individuals.
On January 5, 2026, Canada’s Drug Agency issued its recommendation to not reimburse Tzield (teplizumab) through public drug plans at this time.
This decision means that Tzield is not currently covered under provincial or territorial formularies in Canada.
We will continue to advocate for equitable access to proven therapies and for reimbursement frameworks that evolve alongside scientific progress.
In the meantime, we encourage individuals to consult their healthcare providers to understand whether Tzield or other emerging therapies may be appropriate for them.
For more information on T1D screening in Canada visit canscreent1d.ca/
On January 5, 2026, Canada’s Drug Agency issued its recommendation to not reimburse Tzield (teplizumab) through public drug plans at this time.
This decision means that Tzield is not currently covered under provincial or territorial formularies in Canada.
What is Tzield?
- Tzield is an immunotherapy that targets the underlying autoimmune process responsible for destroying insulin-producing beta cells in the pancreas.
- By modulating this immune response, Tzield has been shown to delay the onset of T1D in individuals already exhibiting an immune cell attack on their beta cells.
- While this therapy does not cure T1D, it represents a significant development in the field of disease-modifying treatments, which aim to alter the course of autoimmune conditions rather than simply manage symptoms.
Current access in Canada
Although Tzield is not publicly reimbursed, it is available in Canada through the manufacturer, Sanofi, via direct channels. This means that individuals who meet eligibility criteria may be able to access the medication out-of-pocket, private insurance or through compassionate access.Looking Ahead
Diabetes Canada recognizes the promise of disease-modifying therapies and the importance of preparing Canada’s health system for innovations in T1D care.We will continue to advocate for equitable access to proven therapies and for reimbursement frameworks that evolve alongside scientific progress.
In the meantime, we encourage individuals to consult their healthcare providers to understand whether Tzield or other emerging therapies may be appropriate for them.
For more information on T1D screening in Canada visit canscreent1d.ca/